GASTRIC CANCER

This early-stage study tests an experimental drug called MOMA-341, taken as a pill, for people with advanced solid tumors that have specific genetic features (MSI-H or dMMR). The study includes up to 132 adults whose cancer has not responded to prior treatments. The main goal is …

This study tests capmatinib, a drug already approved for certain lung cancers, in adults with other rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if their tumors shrink or stop growing for at least 24 weeks. The goal is to fi…

This program provides an experimental drug called AVM0703 to people with various cancers, including brain tumors, breast cancer, and leukemia. It is available in the US when a doctor requests it. So far, 37 patients have received the treatment, and side effects have been mostly m…

This study tests whether using a reinforcement patch on the stapler during stomach cancer surgery can lower the chance of leaks or other complications. About 382 adults with gastric cancer will be randomly assigned to get either the patch or a standard stapler. The main goal is t…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests whether a combination of three drugs (RC48, sintilimab, and SOX chemotherapy) can shrink advanced stomach cancer enough to allow surgical removal. It enrolls 30 adults aged 18-70 with HER2 1+ or 2+ stomach cancer that cannot be removed initially. Participants rec…

This study tests if taking oral sorbitol (a common sugar alcohol) can make standard chemotherapy and immunotherapy work better for people with locally advanced stomach cancer. About 80 adults will receive either sorbitol or a placebo alongside their cancer treatment. The goal is …

This study tests whether adding a gut microbiome supplement (EXL01) to standard immunotherapy (nivolumab) and chemotherapy (FOLFOX) helps shrink tumors in people with advanced stomach cancer. About 120 participants will be randomly assigned to receive either the supplement plus s…

This study compares standard chemotherapy alone versus chemotherapy plus a special procedure called PIPAC (a spray form of chemo delivered directly into the abdomen) for people with stomach cancer that has spread to the lining of the belly. About 106 adults aged 18-75 will take p…

This study tests an experimental drug called M9140 in people with advanced solid tumors (stomach, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a powerful chemotherapy directly to cancer cells. The goal is to see if it can shr…

This trial tests a personalized cancer vaccine made from tumor cells grown in a lab. The cells are modified to boost the immune system, then killed and injected into the patient. The goal is to help people with metastatic melanoma, breast, ovarian, colorectal, gastric, lung, or k…

This study tests three experimental treatments for people with advanced esophageal, stomach, or colorectal cancer that has spread. The goal is to see if these drug combinations can shrink tumors or slow disease progression. About 376 adults aged 18 to 75 will participate, and the…

This study tests a two-step treatment for people with advanced liver or stomach cancer whose disease got worse after immunotherapy. First, a drug called tirapazamine is injected directly into the liver tumor's blood supply, then patients receive nivolumab, an immunotherapy drug. …

This early-phase study tests a new drug called BL-M17D1 in people with advanced HER2-positive or low-HER2 gastrointestinal cancers and other solid tumors. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 20 adults will take part, …

This early-stage study tests a new drug called STRO-004 in about 200 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in m…

This study tests a software tool called myDIET that helps manage nutrition for people with stomach or esophageal junction cancer who are scheduled for surgery. The goal is to see if using the app improves how quickly patients can start additional treatment after surgery. About 60…

This study tests whether adding a new experimental drug (HLX22) to standard treatment can help people with advanced HER2-positive stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 550 adults who have not had prior treatment for the…

This study tests a new drug called JR8603 in people with advanced solid tumors (like stomach or colorectal cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 94 adults will take part in this ear…

This early-phase study tests an experimental drug called MRG007 in people with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors.…

This study tests a new drug called AZD0901, alone or with other cancer drugs, in people with advanced solid tumors that have a specific protein (CLDN18.2). The goal is to see if the drug is safe and can shrink tumors. About 224 adults with stomach, bile duct, or pancreatic cancer…

This early-phase study tests an experimental drug called IVX037, injected directly into tumors, for people with advanced colorectal, gastric, or ovarian cancers that have stopped responding to standard treatments. The study has two parts: first, testing IVX037 alone, and then com…

This study tests a new drug combination (Enhertu plus chemotherapy, with or without pembrolizumab) against the standard treatment for advanced HER2-positive stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 726 adults who have not received prior…

This early-stage study tests a new treatment using a patient's own immune cells, engineered to target a protein called CEA found on certain cancer cells. It is for adults with advanced lung, stomach, colon, rectal, esophageal, or pancreatic cancer who have not responded to standa…

This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) w…

This study compares two surgical methods for removing the upper part of the stomach in people with stomach cancer. The goal is to see which technique causes less acid reflux and improves quality of life. About 60 adults with early to advanced stomach cancer will take part. Resear…

This study is testing whether a new type of radiation therapy guided by MRI is safe and works well for people with gastric, breast, or other cancers. About 70 adults will receive this treatment along with chemotherapy. The goal is to see if the MRI guidance helps doctors target t…

This study tests whether adding the drug neratinib to a standard chemotherapy combination (FOLFOX) plus two targeted drugs (trastuzumab and pembrolizumab) can shrink tumors in people with HER2-positive stomach, esophageal, or gastroesophageal junction cancer. About 36 adults with…

This study tests whether two drugs, avutometinib and defactinib, can shrink tumors and help people with a certain type of advanced stomach cancer live longer. It is for adults whose cancer has spread and who have already tried at least one other treatment. The study will track ho…

This study tests whether combining the immunotherapy drug adebrelimab with other targeted drugs and chemotherapy can shrink stomach or gastroesophageal junction tumors. About 200 adults who have not had prior treatment for their cancer will receive one of several drug combination…

This study tests a new drug called AZD0901 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). About 572 adults who have already tried at least one prior therapy will be randomly assigned to recei…

This study tests a new combination of drugs for people with advanced stomach or gastroesophageal junction cancer that has not responded to initial treatment, including immunotherapy. About 60 participants will receive either a two-drug or three-drug regimen to see if it can slow …

This study tests a new drug (sonesitatug vedotin) plus chemotherapy, with or without another drug (rilvegostomig), in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specific marker (CLDN18.2) and is HER2-negative. About 2,130 participants…

This study is for people with stomach cancer that has spread to a few other places in the body. It tests whether adding surgery to remove the main tumor and some of the spread, along with other local treatments, to a combination of immunotherapy and chemotherapy helps people live…

This early-phase trial tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part.

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack canc…

This early-phase study tests a new drug, SON-DP, in 96 adults with advanced solid tumors, including liver and gastric cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have a measurable tumor and be between 1…

This study tests whether adding an immunotherapy drug (anti-PD-1) and an immune booster (thymalfasin) to standard chemotherapy (SOX) before surgery can help people with stage III stomach or gastroesophageal junction cancer. About 30 adults aged 18-75 will receive the combination,…

This study tests a new treatment for people with certain advanced cancers (like pancreatic, stomach, or colon cancer) that have a specific genetic change called KRAS G12V. The treatment involves taking a patient's own white blood cells, modifying them in a lab to better recognize…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests whether adding heated chemotherapy directly into the abdomen during stomach cancer surgery can help patients live longer and lower the chance of cancer coming back. About 616 adults with advanced stomach cancer will either get standard surgery plus chemotherapy, …

This early-phase study tests a new treatment called Anti-CEA CAR-T for people with advanced solid tumors (like colorectal or stomach cancer) that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target a protein calle…

This early-phase study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatm…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors, including stomach, pancreatic, and bile duct cancers. The main goals are to check the drug's safety, find the best dose, and see how the body process…

This early-phase study tests an experimental pill called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug aims to boost the body's immune system to fight tumors. The main goals are to check safety and see if the drug can shrink or c…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The trial includes 740 participants with 13 different cancer types, such as lung, breast, and prostate cancer. The goal is to see if the …

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, lung, or ovarian cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors, either alone or combined with ot…

This study looks at different second-line drug combinations for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. Researchers want to see which combination works best and is safest. About 250 adults aged 18 to 80 who are o…

This study tests a new drug called GAIA-102, given alone or with another drug (pembrolizumab), for people with advanced stomach or pancreatic cancer that has spread to the belly lining and causes fluid buildup (malignant ascites). The first part checks safety and the best dose; t…

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This study tests new combinations of drugs for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if these combinations can shrink tumors or delay cancer growth. About 163 adults who have not had pr…

This study tests a new drug called datopotamab deruxtecan (Dato-DXd) alone or with other cancer drugs in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gas…

This study tests a combination of two drugs (carilizumab and albumin paclitaxel) as a second treatment for people with advanced stomach cancer. It includes 40 adults who have already tried one prior treatment, with or without immunotherapy. The goal is to see if the combo can slo…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 27 adults will take part in this …

This study is testing a new drug, enzelkitug, for people with advanced solid tumors that have spread or cannot be removed by surgery. The trial includes many cancer types like lung, head and neck, melanoma, breast, and others. The main goal is to check the drug's safety and find …

This early-phase study tests a new drug called TH9619 in people with advanced solid tumors, including colorectal, head and neck, lung, and stomach cancers. The main goal is to find a safe dose and check for side effects. About 43 adults who have already tried at least one standar…

This study tests whether combining two or three drugs (cabozantinib, durvalumab, and tremelimumab) can safely shrink tumors in people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that cannot be removed by surgery will …

This study tests whether taking glutamine by mouth can help people with stomach cancer recover muscle mass and nutrition after having their stomach removed. About 120 adults who had stomach cancer surgery will take glutamine supplements, and researchers will measure changes in mu…

This study tests whether a combination of two drugs (camrelizumab and apatinib) can help people with advanced stomach or gastroesophageal junction cancer live longer compared to standard chemotherapy. The trial includes 550 adults whose cancer worsened after initial treatment. Th…

This study tests whether adding a probiotic (Saccharomyces boulardii) to a standard 4-drug antibiotic treatment can better clear H. pylori infection in people whose previous treatment failed. About 1,248 adults who still have the infection after prior therapy will receive either …

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This study is for people with advanced HER2-positive stomach or esophageal cancer. It tests a drug called trastuzumab deruxtecan (T-DXd) alone or with chemotherapy and/or immunotherapy to see if it can shrink tumors and be safe. About 450 adults will take part. The goal is to con…

This study tests a combination of three drugs (lenvatinib, nivolumab, and chemotherapy) in people with advanced stomach cancer that has spread and caused fluid buildup in the belly. The goal is to see if this treatment can shrink tumors and help patients live longer without the c…

This study tests whether adding a drug called thymosin alpha 1 to standard chemo-radiation and immunotherapy can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 adults who have not yet been treated will be randomly assigned to receive either …

This study tests a new drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About …

This early-phase study tests an experimental drug called BL-M07D1 in 280 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug is safe and can shrink tumors in cancers like breast, lung, stomach, and ovarian cancer. Participants must have tr…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

This early-phase trial tests a new drug (CA-4948) combined with standard chemotherapy and immunotherapy for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. The study aims to find the safest dose and check if the com…

This early-phase study tests a new drug called EXS74539 in about 40 adults with advanced solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrin…

This phase 3 study compares a new two-drug immunotherapy (botensilimab + balstilimab) against the current standard treatment (chemotherapy plus nivolumab) in people with advanced or metastatic stomach or esophageal cancer that has a specific genetic feature (MSI-H/dMMR). The goal…

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors (like lung, colon, head and neck, pancreatic, stomach, or kidney cancer) that have stopped responding to standard treatments. The main goals are to check …

This study looks at whether a diet low in leucine (an amino acid) is safe and can make standard chemotherapy and immunotherapy work better for people with stomach cancer. About 108 adults with locally advanced stomach cancer will follow this special diet alongside their treatment…

This early-phase trial tests a combination of two targeted drugs, neratinib and fam-trastuzumab deruxtecan (Enhertu), in people with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2. Participants must have already tried at le…

This study tests a new drug called AZD4360 in adults with advanced solid tumors, including stomach, gastroesophageal junction, bile duct, and pancreatic cancers that have not responded to prior treatments. The main goals are to find a safe dose and check for side effects, while a…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This early-phase trial tests a new drug called IKS014 in people with advanced HER2-positive solid tumors, including breast, stomach, and gastroesophageal cancers. The drug is designed to deliver a cancer-killing agent directly to HER2-positive tumor cells. The main goals are to f…

This study tests a new treatment that delivers a powerful, short-range radioactive particle directly to cancer cells that have a protein called FAP on their surface. The therapy is given in two steps: first a low-dose imaging version to see if the tumor takes up the drug, then a …

This early-stage study is testing an experimental drug called AZD5863 in adults with advanced stomach, esophageal junction, esophageal, or pancreatic cancers that have spread. The drug is designed to work like a bridge, connecting the patient's own immune cells to cancer cells to…

This is a first-in-human study to test the safety and find the right dose of a new drug called BAL0891. It will be given alone and in combination with other cancer drugs to 260 adults with advanced solid tumors (like certain breast and stomach cancers) or a type of leukemia that …

This early-stage trial is testing the safety of a new two-part treatment for people with advanced HER2-positive solid tumors, such as breast, lung, or gastric cancer. First, a specially designed virus is injected directly into one tumor to help alert the immune system. A few days…

This study aims to create a tool that uses genetic information from tumor tissue to predict whether a stomach cancer patient will respond well to chemotherapy after surgery. By analyzing RNA splicing patterns with machine learning, researchers hope to identify patients who are le…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study is testing a new type of PET scan that looks for a protein called CLDN18.2 on cancer cells. It includes about 56 adults with stomach, pancreatic, bile duct, or esophageal cancers, plus some healthy volunteers. The goal is to see if this scan can accurately find tumors …

This study is testing a simple, non-invasive device called EsophaCap — a sponge in a capsule that you swallow. It collects cells from the food pipe and stomach to look for DNA changes that might signal early cancer or pre-cancer conditions like Barrett's esophagus. The goal is to…

This study tests a new fluorescent dye that targets cancer cells to help doctors see which lymph nodes contain cancer during stomach cancer surgery. About 47 people with early stomach cancer will have their removed lymph nodes examined with this probe. The goal is to avoid removi…

This study tests whether a dye called CYTALUX™, given before surgery, can help surgeons see cancer tissue in real time using a special camera. It includes 15 adults with stomach, esophagus, or appendix cancer who are already scheduled for surgery. The goal is to improve how compl…

This study tests a new imaging agent called [18F]FPyQCP for PET scans to detect five types of cancer: colorectal, ovarian, gastric, invasive lobular breast, and pancreatic. About 71 adults will receive a single dose of the agent to check its safety and how well it finds cancer, e…

This study is testing whether certain chemicals in a person's breath and blood can help detect early-stage gastro-esophageal cancer. Researchers will compare samples from 1000 people, including those with cancer, those with a pre-cancer condition called Barrett's esophagus, and h…

This study is testing a new imaging system that uses a special dye to make cancer cells glow, helping surgeons see and remove them more completely. About 66 adults with colorectal, pancreatic, esophageal, or gastric cancer will take part before their scheduled surgery. The goal i…

This study aims to prevent gastric cancer in Aboriginal people living in remote areas of Taiwan, where rates are higher than in non-Indigenous populations. Researchers will test and treat up to 50,000 adults aged 20-60 for H. pylori infection, a major cause of stomach cancer. The…

This study tests whether a smartphone-based rehab program can reduce complications and improve recovery in 186 gastric cancer patients who receive chemotherapy before surgery. Participants follow a tailored exercise, nutrition, and mental health plan from before surgery until fou…

This study tests a personalized program of diet, exercise, supplements, and stress management for people undergoing surgery for lung, stomach, or esophageal cancer. The goal is to see if this approach improves quality of life, reduces complications, and helps patients feel better…

This study compares a new type of stomach bypass surgery (partial stomach-partitioning gastrojejunostomy) to the standard surgery for people with advanced stomach cancer that blocks food from leaving the stomach. The goal is to see which surgery better helps patients eat again, w…

This study tests a new device called the COMBO Endoscopy Oropharyngeal Airway in 580 obese patients undergoing sedated gastrointestinal endoscopy. The device combines oxygen support, airway management, and monitoring to reduce the risk of low oxygen levels (hypoxia), a common com…

This study tests whether a new device that combines an airway tube, oxygen, and monitoring can reduce low oxygen levels during sedated endoscopy in people with severe obesity (BMI 35 or higher). About 410 participants will be randomly assigned to receive either standard high-flow…

This study looks back at 1,200 patients who had a breathing tube placed during surgery to see how many developed voice box injuries like hoarseness or sore throat. Researchers will review medical records and follow up by phone to find out what factors increase the risk and how lo…

This study looks at whether a blood test can find tiny traces of gastric cancer left behind after surgery, before it grows back. Researchers will analyze particles called exosomal microRNAs in blood samples from 500 people who had their stomach cancer removed. The goal is to catc…

This study collects tissue, blood, urine, and stool samples from 5,000 people undergoing colonoscopy or endoscopy, including those with GI cancers, polyps, or inflammatory bowel disease, as well as healthy volunteers. Researchers aim to find new biomarkers that could lead to earl…

This study uses a 20-25 minute survey to find out which features of diagnostic tests for gastro-esophageal cancer matter most to patients and the general public. Researchers aim to understand preferences and regional differences to improve screening decisions. Over 2,200 adults a…

This study aims to describe the characteristics of 1,000 people with gastric cancer in Algeria, including their demographics, risk factors, symptoms, and how they are diagnosed and treated. By collecting this information, researchers hope to better understand the disease and impr…

This study follows 600 people at higher risk for stomach cancer to learn how precancerous changes in the stomach lining progress or reverse over time. Participants are adults aged 35-84 having an endoscopy for reasons like stomach pain or a family history of stomach cancer. Resea…

This study is building a registry of people with early stomach changes that can lead to cancer, such as gastric atrophy or intestinal metaplasia. Researchers will also include healthy people and those with stomach cancer for comparison. The goal is to learn what makes these early…

This study is building a registry of people with gastric cancer, a family history of it, or a CDH1 gene mutation. Participants fill out online questionnaires and provide saliva, blood, or tissue samples. The goal is to learn more about what causes gastric cancer and whether genet…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors monitor how well treatment is working in people with stomach cancer. The goal is to see if changes in ctDNA levels can predict treatment response or cancer return earlier than standard sc…

This study looks at whether changes in a blood marker called ctDNA can help doctors tell early on if immunotherapy is working for people with advanced cancers like lung, breast, colorectal, stomach, or liver cancer. Researchers will also check other markers like PD-L1 and TMB to …

This study is looking for ways to detect stomach cancer earlier by monitoring certain substances in the blood. Researchers will follow about 192 adults who are at risk for stomach cancer, tracking changes in these biomarkers over time. The goal is to give doctors a warning system…

This study aims to find out how much a specific gene change (CTNNA1) raises the risk for stomach and breast cancer. Researchers will collect family health histories from 100 adults who carry this gene change or are close relatives of a carrier. The goal is to better understand th…

This study is testing whether a dye called indocyanine green, which glows under a special camera, can help surgeons see and remove more lymph nodes during stomach cancer surgery. About 360 adults with advanced stomach cancer will take part. The goal is to see if using this dye ch…

This study looks at genetic differences between the original stomach or esophageal cancer and any brain tumors that spread from it. Researchers will analyze stored tissue samples from 30 patients to see if key markers like HER2, MSI, PD-L1, and CLDN18.2 change. The goal is to und…

This study follows 400 people with gastrointestinal stromal tumors (GISTs) to collect tumor tissue and blood samples for research. Participants are monitored every 6-12 months for up to 10 years before surgery, and then for 5 years after. The goal is to better understand the dise…

This study collects samples from 320 people, including those with solid cancers and those undergoing lung cancer screening, to detect tumor cells and DNA in blood, urine, and bone marrow. The goal is to learn more about how cancer spreads and to improve early detection and person…

This study is testing whether a personalized blood test that looks for tumor DNA can detect stomach cancer recurrence earlier than standard imaging. About 110 people who had chemotherapy and surgery for stage II-III stomach cancer will provide blood samples over time. The goal is…

This study enrolls 620 adults with solid cancers (lung, esophageal, stomach, pancreatic, liver, colorectal) to collect blood, urine, and bone marrow samples. Researchers will measure circulating tumor cells and DNA to see how they relate to cancer recurrence and survival. The goa…

This study looks at whether the bacteria in your gut can help predict how well a combination of immunotherapy and chemotherapy works for advanced stomach cancer. About 300 people with metastatic or locally advanced stomach cancer who have not had chemo or immunotherapy before wil…

This study looks at a specific genetic change called hMLH1 hypermethylation in stomach cancer. Researchers want to understand how this change relates to patient traits and lifestyle, and whether it affects how tumors respond to chemotherapy. By studying 245 patients who had stoma…

This study looks at whether giving heated chemotherapy directly into the abdomen during keyhole surgery can increase PD-L1 levels in stomach cancer that has spread to the lining of the belly. PD-L1 is a protein that helps the immune system recognize cancer cells. The goal is to s…

This study is for people with stomach, pancreas, or bowel cancer who are having surgery, as well as some people without cancer for comparison. The goal is to understand why some patients lose muscle and weight (cachexia) and how it affects their recovery. Researchers will track c…

This study is testing whether an artificial intelligence (AI) model can predict serious bleeding after stomach cancer surgery. Researchers will collect data from 7,000 adults who had their stomach removed due to cancer. The goal is to help doctors decide earlier if a second surge…

This study tests whether daily CT scans can help doctors see and protect the ovaries during pelvic radiation in women under 50 with various cancers. The goal is to keep radiation doses to the ovaries low enough to avoid early menopause and infertility. Ten participants will recei…

This study looks at whether adding a geriatrician (a doctor who specializes in care for older adults) to the cancer care team helps people aged 70 and older with gastrointestinal cancers. Researchers want to see if this approach is practical and if it reduces unplanned hospital v…

This study is creating a large database of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer, how it progresses, and how to improve p…